Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN SODIUM 20 000 UNITS IN DEXTROSE 5 versus SAVAYSA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN SODIUM 20 000 UNITS IN DEXTROSE 5 versus SAVAYSA.
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% vs SAVAYSA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin sodium binds to antithrombin III, causing a conformational change that accelerates the inactivation of thrombin and factor Xa, and to a lesser extent factors IXa, XIa, and XIIa, thereby inhibiting coagulation. It also inhibits platelet aggregation and prolongs clotting times.
Direct inhibitor of factor Xa, thereby decreasing thrombin generation and fibrin clot formation.
Adults: Initial IV bolus 80 units/kg, then continuous IV infusion at 18 units/kg/hour. For therapeutic anticoagulation, adjust to target aPTT 1.5-2.5 times control. Dosing per institutional nomogram.
5 mg orally twice daily for nonvalvular atrial fibrillation; 5 mg orally twice daily for venous thromboembolism treatment after initial parenteral anticoagulation for 5-10 days.
None Documented
None Documented
Terminal half-life 1.5 hours (range 1-3 hours) for therapeutic doses; dose-dependent, with higher doses prolonging half-life; half-life prolonged in hepatic or renal impairment.
Terminal elimination half-life is 10-14 hours; in healthy subjects, mean half-life is approximately 10 hours. Clinically, this supports once-daily dosing. Half-life is prolonged in renal impairment (e.g., up to 17 hours in severe renal impairment).
Renal: 50-60% as unchanged drug via glomerular filtration; hepatic metabolism (desulfation) accounts for minor clearance; fecal elimination negligible (<1%).
Eliminated primarily via renal excretion of unchanged drug (approximately 82% of an oral dose is excreted in urine as edoxaban). Fecal/biliary excretion accounts for about 8%. Minor metabolism (<10%) via hydrolysis (mediated by carboxylesterase 1) and conjugation, with metabolites excreted renally or in feces.
Category A/B
Category C
Anticoagulant
Anticoagulant, Direct Factor Xa Inhibitor